Transave, Inc., reported positive clinical trial results on its lead investigational drug, ARIKACE™ (liposomal amikacin for inhalation), an antibiotic that is entering Phase III development for the treatment of chronic lung infections. The results demonstrate significant clinical benefit and complete the company's Phase II program for the treatment of lung infections due to the bacterium, Pseudomonas aeruginosa in cystic fibrosis (CF) patients.

The data from the Phase II clinical program in CF patients with Pseudomonas lung infections indicate that ARIKACE, delivered at a dose of 560 mg once daily via an eFlow® Nebulizer System from PARI Pharma GmbH for 28 consecutive days, demonstrated superior clinical benefit compared to placebo as measured by significant and sustained improvement in lung function and reduction in Pseudomonas density. This benefit was sustained over multiple cycles as observed in an open-label long-term study. In addition, ARIKACE was well-tolerated with overall events reported as consistent with those expected in a population of CF patients receiving inhaled medicines. Results were presented today at the Cystic Fibrosis Foundation's 24th annual North American Cystic Fibrosis Conference (NACFC) in Baltimore, Maryland, by JP Clancy, MD, Professor, Director, and Raymond K. Lyrene Chair in Pulmonology, Department of Pediatrics, University of Alabama at Birmingham and Children's Hospital of Alabama.

"The sustained improvement in lung function with significant reduction in bacterial density with ARIKACE has now been shown consistently in Phase II studies in patients with cystic fibrosis who have chronic Pseudomonas lung infections," said Renu Gupta, MD, Transave's Executive Vice President for Development and Chief Medical Officer. "These consistent results suggest that ARIKACE has the potential to improve upon the standard of care in the treatment of chronic Pseudomonas lung infections, and support the launch of Phase III studies to confirm efficacy and safety of ARIKACE."

New data were presented from an open label study that was designed to evaluate ARIKACE over multiple treatment cycles in CF patients with Pseudomonas lung infections. Forty-nine patients were enrolled to receive ARIKACE 560 mg daily for 28 days of therapy using a novel inhalation device, the eFlow® Nebulizer System (PARI Pharma GmbH), followed by a 56-day off-treatment observation period for each cycle. FEV1 increased significantly among patients receiving 560 mg of ARIKACE, with a relative improvement from baseline in pulmonary function (FEV1) of 8.4% (95% CI +4.7%, +12.0%; p less than or equal to 0.0001) at the end of treatment during cycles one to five. More than three quarters of the improvement in lung function was sustained at the end of the 56-day off-treatment period during the five cycles (about 14 months) with a relative improvement from baseline in FEV1 of 6.5% (95% CI +2.5%, +10.4%; p=0.0018).

Data were also presented from two placebo controlled studies. In the first placebo controlled study conducted in Europe, ARIKACE was administered once daily for 28 days at 280 mg and 560 mg dosages using the eFlow® Nebulizer System. In the second placebo controlled study conducted in U.S., ARIKACE was administered once daily for 28 days at 70 mg, 140 mg and 560 mg doses also using the eFlow® Nebulizer System.

The studies were prospectively designed to allow for pooled analyses of data. Improvements in lung function were dose-related, with the 560 mg dose resulting in the greatest improvement in lung function which was sustained for 28 days after treatment ended. Specifically, FEV1 increased significantly among patients receiving 560 mg of ARIKACE, with a relative change from baseline in FEV1 of 8.1% versus 1.1% for placebo (p= 0.033). The treatment effect was sustained for 28 days off treatment at Day 56, with a mean improvement in FEV1 for ARIKACE 560 mg versus placebo of 12.5% (p=0.003).

"Consistent results with once-daily ARIKACE demonstrating clinically important improvements in lung function that are sustained during the off treatment period are very encouraging for the treatment of CF patients with Pseudomonas lung infections," said Dr. Clancy. "The CF treating community looks forward to the initiation and completion of Phase III clinical trials and to potentially providing these benefits to our CF patients."

Cystic Fibrosis Foundation Therapeutics, Inc., a nonprofit affiliate of the Cystic Fibrosis Foundation, provided $3.9 million to support the development of ARIKACE. The Foundation is the leading organization devoted to curing and controlling cystic fibrosis.


ARIKACE is a form of the antibiotic amikacin, which is enclosed in nanocapsules of lipid called liposomes. This advanced pulmonary liposome technology prolongs the release of amikacin in the lungs while minimizing systemic exposure. The treatment uses biocompatible lipids endogenous to the lung that are formulated into small (0.3 micron), neutral liposomes that enable penetration of the biofilm.

The company also previously announced positive Phase II results in September 2009 in the treatment of non-CF bronchiectasis patients who have Pseudomonas lung infections.

Transave and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will collaborate on the planning, design and implementation of a clinical trial expected to begin in the first half of next year to evaluate ARIKACE in patients with nontuberculous mycobacteria (NTM) lung disease who have failed to respond to standard, guideline-based treatment regimens. Current treatment requires lengthy multi-drug regimens that are often poorly tolerated and not very effective. No new drugs have been assessed in clinical trials for this disease in many years.

ARIKACE has been granted orphan drug status in the United States by the FDA, and has received an orphan drug designation in Europe by the European Medicines Agency for the treatment of Pseudomonas infections in patients with CF.

Source: Transave, Inc